Ocular Therapeutix (NASDAQ:OCUL) Announces Quarterly Earnings Results

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.09), Zacks reports. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Ocular Therapeutix Trading Up 3.2 %

OCUL stock opened at $8.80 on Monday. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a twelve month low of $4.79 and a twelve month high of $11.78. The company has a market cap of $1.40 billion, a P/E ratio of -6.67 and a beta of 1.51. The business has a fifty day moving average of $7.40 and a 200-day moving average of $8.39.

Wall Street Analysts Forecast Growth

OCUL has been the subject of several analyst reports. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. William Blair initiated coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.38.

Insider Activity at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Donald Notman sold 11,119 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is owned by company insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.